These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 374242)

  • 1. Suppression of the humoral immune response by particulate material extracted from spleen cell subpoulations of MOPC-315 tumor-bearing mice.
    Kleinman R
    Immunol Commun; 1979; 8(2):131-43. PubMed ID: 374242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloma-induced immunosuppression: a multistep mechanism.
    Katzmann JA
    J Immunol; 1978 Oct; 121(4):1405-9. PubMed ID: 701801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
    Miura T; Ghanta VK; Hiramoto RN
    Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocompetence status as related to growth progression of mouse MOPC-315 plasmacytoma.
    Rashid G; Ophir R; Pecht M; Ben-Efraim S
    In Vivo; 1989; 3(4):279-84. PubMed ID: 2535271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Mokyr MB
    Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of the concomitant presence of palpable MOPC-315 tumor in stimulation of splenocytes by C-type MOPC-315 virus in vitro.
    Schwarzbard Z; Ophir R; Gotlieb-Stematsky T; Benefraim S
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1069-75. PubMed ID: 2998801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Release of immunosuppressive factor(s) by MOPC-315 murine plasmacytoma cells: a possible mechanism of defence.
    Bomstein Y; Ophir R; Harshemes H; Ben-Efraim S
    Anticancer Res; 1993; 13(6A):2125-9. PubMed ID: 8297124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB; Pyle JM; Dray S
    Cancer Immunol Immunother; 1984; 16(3):162-9. PubMed ID: 6561068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
    Mokyr MB; Barker E
    Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
    Gorelik L; Prokhorova A; Mokyr MB
    Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the immune response in vitro and in vivo by splenocytes from tumor-bearing mice.
    Specter SC; Kamo I; Friedman H
    Adv Exp Med Biol; 1976; 66():457-63. PubMed ID: 817575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of antibody responses in allogeneic mice by products of lymphoid tissue. II. Lack of antigenic specificity and immunogenetic requirements of allogeneic suppressive factor (ASF).
    Yonkosky D; Buffett RF; Bennett M
    J Immunol; 1976 Jun; 116(6):1695-703. PubMed ID: 58047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunosuppressive substance in mice bearing plasmacytomas.
    Tanapatchaiyapong P; Zolla S
    Science; 1974 Nov; 186(4165):748-50. PubMed ID: 4547576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune response of mice treated with anti-mu antibodies: the effect on antibody-forming cells, their precursors and helper cells assayed in vitro.
    Gordon J; Murgita RA; Tomasi TB
    J Immunol; 1975 Jun; 114(6):1808-12. PubMed ID: 805179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression in plasmacytoma: induction of suppressor cells.
    Chen Y; Hwang LT; Heller P
    Clin Exp Immunol; 1982 Jan; 47(1):191-6. PubMed ID: 6212173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
    Barker E; Wise JA; Dray S; Mokyr MB
    Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
    Weiskirch LM; Barker E; Mokyr MB
    Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
    Takesue BY; Bartik MM; Mokyr MB
    Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoma spleen colonization: a sensitive, quantitative in vivo assay for idiotype-specific immune suppression of MOPC-315.
    Daley MJ; Bridges SH; Lynch RG
    J Immunol Methods; 1978; 24(1-2):47-56. PubMed ID: 82590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.